非小细胞肺癌患者ALK表达与临床病理特征对比分析

目的 研究100例非小细胞肺癌（NSCLC）患者间变性淋巴瘤激酶（ALK）的表达，并与其临床病理特征进行统计学分析。方法 收集安徽医科大学第二附属医院2016年1月至2017年10月收治的NSCLC患者标本100例，采用全自动免疫组化法检测ALK表达情况，统计分析ALK表达与其临床病理特征。结果 100例NSCLC患者中，6例ALK阳性，阳性表达率为6.00%。不同年龄、不同肿块直径、不同病理分型患者的ALK阳性表达率进行比较，差异有统计学意义（P<0.05）。而不同性别、是否吸烟、发生部位以及是否淋巴结转移间患者的ALK阳性表达率进行比较，差异均无统计学意义（P>0.05）。结论 NSCLC患者ALK的表达情况与患者的年龄、肿块直径和病理分型有关，可为临床相关疾病的诊疗提供了重要参考。

Expression of ALK in non-small cell lung cancer and contrastive analysis of its clinicopathological characteristics

Objective To investigate the expression of ALK in 100 NSCLC patients, and further perform the contrastive analysis of its clinicopathological characteristics. Methods The clinical data of 100 cases of NSCLC patients hospitalized in the Second Hospital of Anhui Medical University fromJan. 2016 to Oct. 2017were collected,the expression of ALK was detectedby full-automatic immunohistochemistry, and the contrastive analysis between ALK and clinicopathological features was performedby SPSS statistical analysis. Results There were 6 cases of ALK positive patients in 100 cases, and the positive rate was 6%. The positive expression rate of ALK in patients with different age, tumor diameter and pathological type was significantly different (P<0.05). However, there was no marked difference in the positive expression rate of ALK among patients with different sex, smoking, location of occurrence and lymph node metastasis(P>0.05). Conclusion The expression of ALK inNSCLC patients is related to their age, lump size and pathological classification, which may provide important reference for the clinical diagnosis and treatment.